Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy. A feasibility study

Objective: The aim of this study is to evaluate the implementation of the elements of enhanced recovery (ERAS) protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for metastatic ovarian cancer. ERAS protocols have shown improvement in the peri...

Full description

Saved in:
Bibliographic Details
Main Authors: Anastasios Pandraklakis, Chrysoula Liakou, MariaClelia La Russa, Rocio Ochoa-Ferraro, Adam Stearns, Nikolaos Burbos
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Gynecologic Oncology Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578924002157
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850111070329372672
author Anastasios Pandraklakis
Chrysoula Liakou
MariaClelia La Russa
Rocio Ochoa-Ferraro
Adam Stearns
Nikolaos Burbos
author_facet Anastasios Pandraklakis
Chrysoula Liakou
MariaClelia La Russa
Rocio Ochoa-Ferraro
Adam Stearns
Nikolaos Burbos
author_sort Anastasios Pandraklakis
collection DOAJ
description Objective: The aim of this study is to evaluate the implementation of the elements of enhanced recovery (ERAS) protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for metastatic ovarian cancer. ERAS protocols have shown improvement in the perioperative outcomes of patients who underwent cytoreductive surgery for metastatic ovarian cancer by reducing the length of stay as well as the postoperative complications and by improving patients’ postoperative experience. Methods: This is a feasibility study involving retrospective analysis from (31) patients who underwent cytoreductive surgery and HIPEC versus (35) a control group that underwent cytoreductive surgery only, prior to the introduction of the HIPEC programme for metastatic ovarian cancer. All patients had undergone neoadjuvant chemotherapy prior to surgery. We compared the compliance for each element of the ERAS protocol between the two study groups. Results: We analyzed data from 66 patients, 31 in HIPEC group and 35 in the control goup. We found no significant difference in the patients’ characteristics between the two groups and there were no differences in the implementation of 8 elements of the ERAS protocols (100 % for both groups). The use of nasogastric tube was more frequently observed in patients undergoing surgery and HIPEC compared to those undergoing surgery alone (42 % vs 0 %, respectively; p < 0.001). The number of patients who were mobilized on the first postoperative day was higher in the group undergoing surgery and HIPEC (87.1 % vs 57.1 %, respectively; p = 0.007), however there was no significant difference in the percentage of patients that had early removal of the urinary catheter (p = 0.12), nor in the percentage of patients that received early feeding (p = 0.18). Finally, there were no statistically significant differences in the complication rates, the length of hospital stay and the re-admission rates between the two groups. Conclusion: Enhanced recovery protocols can be implemented safely in patients undergoing cytoreductive surgery and HIPEC for ovarian cancer.
format Article
id doaj-art-2b066f2ff44c4cf1bddccd2e8e8f5ac8
institution OA Journals
issn 2352-5789
language English
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Gynecologic Oncology Reports
spelling doaj-art-2b066f2ff44c4cf1bddccd2e8e8f5ac82025-08-20T02:37:42ZengElsevierGynecologic Oncology Reports2352-57892024-12-015610153610.1016/j.gore.2024.101536Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy. A feasibility studyAnastasios Pandraklakis0Chrysoula Liakou1MariaClelia La Russa2Rocio Ochoa-Ferraro3Adam Stearns4Nikolaos Burbos5Department of Gynaecology and Gynaecological Oncology, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UK; Corresponding author.Department of Gynaecology and Gynaecological Oncology, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UKDepartment of Gynaecology and Gynaecological Oncology, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UKDepartment of Anesthesia, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UKDepartment of Surgery, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UKDepartment of Gynaecology and Gynaecological Oncology, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UKObjective: The aim of this study is to evaluate the implementation of the elements of enhanced recovery (ERAS) protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for metastatic ovarian cancer. ERAS protocols have shown improvement in the perioperative outcomes of patients who underwent cytoreductive surgery for metastatic ovarian cancer by reducing the length of stay as well as the postoperative complications and by improving patients’ postoperative experience. Methods: This is a feasibility study involving retrospective analysis from (31) patients who underwent cytoreductive surgery and HIPEC versus (35) a control group that underwent cytoreductive surgery only, prior to the introduction of the HIPEC programme for metastatic ovarian cancer. All patients had undergone neoadjuvant chemotherapy prior to surgery. We compared the compliance for each element of the ERAS protocol between the two study groups. Results: We analyzed data from 66 patients, 31 in HIPEC group and 35 in the control goup. We found no significant difference in the patients’ characteristics between the two groups and there were no differences in the implementation of 8 elements of the ERAS protocols (100 % for both groups). The use of nasogastric tube was more frequently observed in patients undergoing surgery and HIPEC compared to those undergoing surgery alone (42 % vs 0 %, respectively; p < 0.001). The number of patients who were mobilized on the first postoperative day was higher in the group undergoing surgery and HIPEC (87.1 % vs 57.1 %, respectively; p = 0.007), however there was no significant difference in the percentage of patients that had early removal of the urinary catheter (p = 0.12), nor in the percentage of patients that received early feeding (p = 0.18). Finally, there were no statistically significant differences in the complication rates, the length of hospital stay and the re-admission rates between the two groups. Conclusion: Enhanced recovery protocols can be implemented safely in patients undergoing cytoreductive surgery and HIPEC for ovarian cancer.http://www.sciencedirect.com/science/article/pii/S2352578924002157
spellingShingle Anastasios Pandraklakis
Chrysoula Liakou
MariaClelia La Russa
Rocio Ochoa-Ferraro
Adam Stearns
Nikolaos Burbos
Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy. A feasibility study
Gynecologic Oncology Reports
title Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy. A feasibility study
title_full Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy. A feasibility study
title_fullStr Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy. A feasibility study
title_full_unstemmed Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy. A feasibility study
title_short Implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy. A feasibility study
title_sort implementation of enhanced recovery protocols in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic ovarian cancer following neoadjuvant chemotherapy a feasibility study
url http://www.sciencedirect.com/science/article/pii/S2352578924002157
work_keys_str_mv AT anastasiospandraklakis implementationofenhancedrecoveryprotocolsinpatientsundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapyformetastaticovariancancerfollowingneoadjuvantchemotherapyafeasibilitystudy
AT chrysoulaliakou implementationofenhancedrecoveryprotocolsinpatientsundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapyformetastaticovariancancerfollowingneoadjuvantchemotherapyafeasibilitystudy
AT mariaclelialarussa implementationofenhancedrecoveryprotocolsinpatientsundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapyformetastaticovariancancerfollowingneoadjuvantchemotherapyafeasibilitystudy
AT rocioochoaferraro implementationofenhancedrecoveryprotocolsinpatientsundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapyformetastaticovariancancerfollowingneoadjuvantchemotherapyafeasibilitystudy
AT adamstearns implementationofenhancedrecoveryprotocolsinpatientsundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapyformetastaticovariancancerfollowingneoadjuvantchemotherapyafeasibilitystudy
AT nikolaosburbos implementationofenhancedrecoveryprotocolsinpatientsundergoingcytoreductivesurgeryandhyperthermicintraperitonealchemotherapyformetastaticovariancancerfollowingneoadjuvantchemotherapyafeasibilitystudy